BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9480	Companies
185527	Keywords
117915	Articles
99372	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 08/20/2025 at 09:05, 3 months 16 days ago

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
BioNxt announces fast-tracked U.S. patent filing for BNT23001 sublingual thin-film cladribine formulation targeting neurological autoimmune disorders. Broad international patent core claims accepted for platform-level protection

Autoimmune Diseases Drug Delivery Neurological Disorders Patent Filing BioNxt
BRIEF

published on 08/09/2025 at 01:05, 3 months 27 days ago

BioNxt Solutions Completes Oversubscribed Convertible Debenture Offering

Private Placement Convertible Debenture Warrants Product Development BioNxt Solutions
BRIEF

published on 08/09/2025 at 01:05, 3 months 27 days ago

BioNxt Solutions finalise son offre d'obligations convertibles sursouscrite

Placement Privé Développement De Produits Mandats Obligation Convertible Solutions BioNxt
PRESS RELEASE

published on 08/09/2025 at 01:00, 3 months 27 days ago

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising $241,200 for convertible debentures and issuing Warrants. Funds intended for product development and IP filings

Private Placement Warrants Convertible Debentures BioNxt Solutions Inc. Product Development
BRIEF

published on 08/05/2025 at 09:10, 4 months ago

BioNxt Solutions Advances Patent Protection for MS Treatment

Multiple Sclerosis Drug Delivery Technology Patent Protection BioNxt Solutions Sublingual Cladribine
BRIEF

published on 08/05/2025 at 09:10, 4 months ago

BioNxt Solutions renforce la protection des brevets pour le traitement de la sclérose en plaques

Sclérose En Plaques Technologie D'administration De Médicaments Solutions BioNxt Cladribine Sublinguale Protection Par Brevet
PRESS RELEASE

published on 08/05/2025 at 09:05, 4 months ago

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
BioNxt Solutions Inc. makes significant progress in global patent portfolio with EPO and EAPO confirming acceptance of core claims for sublingual Cladribine thin-film formulation. Focus on innovation in MS treatment

BioNxt Solutions Inc. Patent Portfolio Cladribine EPO EAPO
BRIEF

published on 07/26/2025 at 00:05, 4 months 10 days ago

BioNxt Solutions clôture la première tranche de son placement d'obligations

Obligations Convertibles Placement Privé Développement De Produits Mandats Solutions BioNxt
BRIEF

published on 07/26/2025 at 00:05, 4 months 10 days ago

BioNxt Solutions Closes First Tranche of Debenture Placement

Private Placement Warrants Convertible Debentures Product Development BioNxt Solutions
PRESS RELEASE

published on 07/26/2025 at 00:00, 4 months 10 days ago

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes first tranche of non-brokered private placement, raising $1,009,200 for drug delivery tech and IP development. Securities subject to statutory hold until Nov 26, 2025

Private Placement Convertible Debentures BioNxt Solutions Inc. Intellectual Property Drug Delivery Technologies

Accesswire

Published on 12/05/2025 at 18:45, 33 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 58 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 18 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 3 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 2 hours 18 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 20 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 52 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 3 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 1 hour 26 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 1 hour 32 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 7 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 4 hours 7 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 5 hours 19 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE